How to buy Telesis Bio stock (TBIO)

Telesis Bio is a medical devices business based in the US. Telesis Bio shares (TBIO) are listed on the PINK and all prices are listed in US Dollars. Its last market close was $0.47 – a decrease of 26.36% over the previous week. Telesis Bio employs 137 staff and has a trailing 12-month revenue of around $15.6 million.

Our top picks for where to buy Telesis Bio stock

Buy Telesis Bio stock from these online trading platforms

Compare special offers, low fees and a wide range of investment options among top trading platforms.

Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.

Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.

Telesis Bio stock price (PINK: TBIO)

Use our graph to track the performance of TBIO stocks over time.

Telesis Bio shares at a glance

• Key figures

Information last updated 2024-11-21.

Latest market close	$0.47
52-week range	$0.35 - $15.46
50-day moving average more info button	$2.04
200-day moving average more info button	$4.65
Wall St. target price	$4.00
PE ratio more info button	N/A
Dividend yield more info button	N/A
Earnings per share (TTM) more info button	$-30.42

Telesis Bio price performance over time

Historical closes compared with the close of $0.47 from 2024-12-20

1 week (2024-12-16)	-26.36%
1 month (2024-11-22)	-48.35%
3 months (2024-09-23)	-86.83%
6 months (2024-06-21)	-86.38%

1 year (2023-12-22)	20.51%
2 years (2022-12-23)	-97.89%
3 years (2021-12-23)	113.58
5 years (2019-12-20)	N/A

Telesis Bio financials

Revenue TTM	$15.6 million
Gross profit TTM	$15.6 million
Return on assets TTM	-29.39%
Return on equity TTM	-176.11%
Profit margin	-292.59%
Book value	$-15.35
Market Capitalization more info button	$1.7 million

TTM: trailing 12 months

Telesis Bio share dividends

We're not expecting Telesis Bio to pay a dividend over the next 12 months.

Have Telesis Bio's shares ever split?

Telesis Bio's shares were split on a 1:18 basis on 8 May 2024 . So if you had owned 18 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Telesis Bio shares – just the quantity. However, indirectly, the new 1700% higher share price could have impacted the market appetite for Telesis Bio shares which in turn could have impacted Telesis Bio's share price.

Telesis Bio share price volatility

Over the last 12 months, Telesis Bio's shares have ranged in value from as little as $0.3461 up to $15.462. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (PINK average) beta is 1, while Telesis Bio's is 1.758. This would suggest that Telesis Bio's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).

Telesis Bio overview

Telesis Bio, Inc. , a synthetic biology company, manufactures and sells synthetic biology instruments, reagents, and associated products and related services, primarily to pharmaceutical and academic laboratories worldwide. The company offers BioXp 3250 system and BioXp 9600 system that empower researchers to go from a digital DNA sequence to endpoint-ready synthetic deoxyribonucleic acid (DNA) and messenger ribonucleic acid (mRNA) with onboard next generation sequencing (NGS) library preparation; BioXp portal, an online portal that offers an intuitive guided workflow and design tools for building new DNA sequences and assembling them into vectors of choice, as well as mRNA constructs; and BioXp De Novo kits, which contains building blocks and reagents, including proprietary Gibson assembly branded reagents for specific synthetic biology workflow applications. It also provides BioXp Select kits that offers to use non-telesis bio DNA while using the BioXp system to perform synthetic biology workflow applications, such as cloning, mRNA generation from plasmid, and cell free amplification; BioXp Next Generation Sequencing kits, which contains reagents to go from DNA or RNA to a sequencer-ready library; Benchtop reagents that contains the reagents to proceed specific synthetic biology workflow on the benchtop using products generated on the BioXp system; and custom Gibson short oligo ligation assembly enzymatic DNA synthesis solutions, which is designed to construct synthetic DNA, RNA, and proteins for development of mRNA-based vaccines, diagnostics, therapeutics, and personalized medicines. The company serves its products to government institutions, contract research organizations, and synthetic biology companies. The company was formerly known as Codex DNA, Inc. and changed its name to Telesis Bio Inc.

Frequently asked questions

What percentage of Telesis Bio is owned by insiders or institutions?
Currently 30.666% of Telesis Bio shares are held by insiders and 33.175% by institutions. How many people work for Telesis Bio?
Latest data suggests 137 work at Telesis Bio. When does the fiscal year end for Telesis Bio?
Telesis Bio's fiscal year ends in December. Where is Telesis Bio based?
Telesis Bio's address is: 10431 Wateridge Circle, San Diego, CA, United States, 92121-2993